These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25186430)

  • 1. 11C-Choline PET/pathology image coregistration in primary localized prostate cancer.
    Grosu AL; Weirich G; Wendl C; Prokic V; Kirste S; Geinitz H; Souvatzoglou M; Gschwend JE; Schwaiger M; Molls M; Weber WA; Treiber U; Krause BJ
    Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2242-8. PubMed ID: 25186430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens.
    Bundschuh RA; Wendl CM; Weirich G; Eiber M; Souvatzoglou M; Treiber U; Kübler H; Maurer T; Gschwend JE; Geinitz H; Grosu AL; Ziegler SI; Krause BJ
    Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):824-31. PubMed ID: 23389430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-fluorocholine PET-guided target volume delineation techniques for partial prostate re-irradiation in local recurrent prostate cancer.
    Wang H; Vees H; Miralbell R; Wissmeyer M; Steiner C; Ratib O; Senthamizhchelvan S; Zaidi H
    Radiother Oncol; 2009 Nov; 93(2):220-5. PubMed ID: 19767115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does 11C-choline PET-CT contribute to multiparametric MRI for prostate cancer localisation?
    Van den Bergh L; Isebaert S; Koole M; Oyen R; Joniau S; Lerut E; Deroose CM; De Keyzer F; Van Poppel H; Haustermans K
    Strahlenther Onkol; 2013 Sep; 189(9):789-95. PubMed ID: 23797481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the PET component of simultaneous [(18)F]choline PET/MRI in prostate cancer: comparison with [(18)F]choline PET/CT.
    Wetter A; Lipponer C; Nensa F; Heusch P; Rübben H; Altenbernd JC; Schlosser T; Bockisch A; Pöppel T; Lauenstein T; Nagarajah J
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):79-88. PubMed ID: 24085502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation Treatment of Lymph Node Recurrence from Prostate Cancer: Is 11C-Choline PET/CT Predictive of Survival Outcomes?
    Incerti E; Fodor A; Mapelli P; Fiorino C; Alongi P; Kirienko M; Giovacchini G; Busnardo E; Gianolli L; Di Muzio N; Picchio M
    J Nucl Med; 2015 Dec; 56(12):1836-42. PubMed ID: 26405166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis.
    Turkbey B; Mena E; Shih J; Pinto PA; Merino MJ; Lindenberg ML; Bernardo M; McKinney YL; Adler S; Owenius R; Choyke PL; Kurdziel KA
    Radiology; 2014 Mar; 270(3):849-56. PubMed ID: 24475804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques.
    Piert M; Park H; Khan A; Siddiqui J; Hussain H; Chenevert T; Wood D; Johnson T; Shah RB; Meyer C
    J Nucl Med; 2009 Oct; 50(10):1585-93. PubMed ID: 19759109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [11C]Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomy.
    Schwarzenböck SM; Knieling A; Souvatzoglou M; Kurth J; Steiger K; Eiber M; Esposito I; Retz M; Kübler H; Gschwend JE; Schwaiger M; Krause BJ; Thalgott M
    Oncotarget; 2016 Sep; 7(39):63747-63757. PubMed ID: 27572317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT.
    Ceci F; Castellucci P; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Ntreta M; Lodi F; Martorana G; Fanti S
    Eur J Nucl Med Mol Imaging; 2014 May; 41(5):878-86. PubMed ID: 24346416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI versus ⁶⁸Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer.
    Zamboglou C; Wieser G; Hennies S; Rempel I; Kirste S; Soschynski M; Rischke HC; Fechter T; Jilg CA; Langer M; Meyer PT; Bock M; Grosu AL
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):889-897. PubMed ID: 26592938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there an additional value of ¹¹C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules?
    Van den Bergh L; Koole M; Isebaert S; Joniau S; Deroose CM; Oyen R; Lerut E; Budiharto T; Mottaghy F; Bormans G; Van Poppel H; Haustermans K
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1486-92. PubMed ID: 22284686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging prostate cancer with 11C-choline PET/CT.
    Reske SN; Blumstein NM; Neumaier B; Gottfried HW; Finsterbusch F; Kocot D; Möller P; Glatting G; Perner S
    J Nucl Med; 2006 Aug; 47(8):1249-54. PubMed ID: 16883001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer.
    Picchio M; Briganti A; Fanti S; Heidenreich A; Krause BJ; Messa C; Montorsi F; Reske SN; Thalmann GN
    Eur Urol; 2011 Jan; 59(1):51-60. PubMed ID: 20869161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of metabolic tumor volume and 11C-choline uptake with the pathology of prostate cancer: evaluation by use of simultaneously recorded MR and PET images.
    Yoneyama T; Tateishi U; Terauchi T; Inoue T
    Jpn J Radiol; 2014 Mar; 32(3):155-63. PubMed ID: 24446034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [11C]Choline-PET/CT for outcome prediction of salvage radiotherapy of local relapsing prostate carcinoma.
    Reske SN; Moritz S; Kull T
    Q J Nucl Med Mol Imaging; 2012 Oct; 56(5):430-9. PubMed ID: 23069922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 11C-choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer.
    Ceci F; Castellucci P; Graziani T; Schiavina R; Chondrogiannis S; Bonfiglioli R; Costa S; Virgolini IJ; Rubello D; Fanti S; Colletti PM
    Clin Nucl Med; 2015 May; 40(5):e265-70. PubMed ID: 25783519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer.
    Souvatzoglou M; Eiber M; Takei T; Fürst S; Maurer T; Gaertner F; Geinitz H; Drzezga A; Ziegler S; Nekolla SG; Rummeny EJ; Schwaiger M; Beer AJ
    Eur J Nucl Med Mol Imaging; 2013 Oct; 40(10):1486-99. PubMed ID: 23817684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G; Picchio M; Parra RG; Briganti A; Gianolli L; Montorsi F; Messa C
    Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.